dr. agarwal on candidates for docetaxel versus abiraterone and prednisone
Published 7 years ago • 218 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:01
dr. agarwal on the advantages of docetaxel in prostate cancer
-
0:45
dr. hahn on patients with prostate cancer whom neither docetaxel or abiraterone is an option
-
1:26
dr. agarwal on potential agents for metastatic hormone-sensitive prostate cancer
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
1:44
dr. agarwal on the stampede and latitude trials for prostate cancer
-
5:59
apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mcrpc
-
1:19
comparing abiraterone and docetaxel in prostate cancer treatment
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer
-
1:18
dr. aggarwal on the future of adt for patients with prostate cancer
-
1:32
dr. agarwal on treatment for newly diagnosed prostate cancer
-
1:32
dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
0:20
copy of dr. hahn discusses abiraterone versus docetaxel in prostate cancer
-
1:37
dr. agarwal on drug development in metastatic castration-sensitive prostate cancer
-
4:38
stampede: abiraterone acetate plus prednisolone or docetaxel
-
1:37
dr. oh discusses the use of abiraterone and docetaxel in prostate cancer
-
1:05
dr. agarwal on androgen receptor inhibitors for prostate cancer
-
5:16
exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
-
1:50
a phase i trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in mcrpc